1. Introduction and Significance

Sofosbuvir represents a paradigm shift in the management of chronic hepatitis C virus (HCV) infection, particularly since its approval by the FDA in 2013. As a direct-acting antiviral (DAA), sofosbuvir targets HCV replication at the molecular level, offering high cure rates and improved tolerability compared to older interferon-based regimens. Its introduction has transformed HCV therapy from a prolonged, toxic course to a short-course, well-tolerated regimen with cure rates exceeding 95% in most patient populations.

2. Mechanism of Action

Sofosbuvir is a nucleotide analog and RNA-dependent RNA polymerase (RdRp) inhibitor of HCV NS5B polymerase. Upon oral administration, it is phosphorylated intracellularly to its active metabolite, GS-461203, which acts as a competitive substrate for the viral RNA polymerase.

• Binding Specificity: Sofosbuvir binds specifically to the GDD motif (Gly-Asp-Asp) in the NS5B active site, which coordinates two Mg²⁺ ions essential for catalytic activity.
• Chain Termination: Once incorporated into nascent HCV RNA, sofosbuvir acts as a chain terminator, halting further viral RNA elongation and replication.

This mechanism confers a high genetic barrier to resistance, especially when used in combination regimens.

3. Pharmacokinetics

• Bioavailability: ~95% (oral, food-independent)
• Half-life: ~12–15 hours
• Metabolism: Minimal hepatic metabolism; primarily excreted unchanged in urine (~90%)
• Renal Impairment: Dose adjustment not required for mild-moderate impairment; caution in severe renal impairment

4. Indications and Evidence-Based Use

Sofosbuvir is indicated as part of combination regimens for the treatment of chronic HCV infection, including:

• Genotype 1: (6-12 weeks depending on prior therapy, ribavirin use, and cirrhosis status)
• Genotype 2: 12 weeks with or without ribavirin
• Genotype 3: 12–24 weeks (with or without ribavirin), especially in patients with advanced fibrosis/cirrhosis

Regimens commonly include:

• Sofosbuvir + Velpatasvir (Epclusa®): Pan-genotypic, recommended first-line for most patients
• Sofosbuvir + Ribavirin: For certain genotypes or special populations

Guidelines from AASLD/IDSA (2022) recommend sofosbuvir-containing regimens as preferred due to high efficacy and safety.

5. Dosing Considerations

• Adults: 400 mg once daily, with or without food
• Pediatrics: Weight-based dosing; pediatric formulations available
• Renal Impairment: No dose adjustment needed for mild-moderate impairment; avoid in severe renal failure unless absolutely necessary

6. Adverse Effects

Sofosbuvir is generally well tolerated. Most common adverse events (AEs) reported in clinical trials:

• Headache
• Fatigue
• Nausea/diarrhea
• Abdominal pain
• Insomnia

Serious AEs (rare):

• Hemolytic anemia (especially with ribavirin coadministration)
• Severe hypersensitivity reactions
• Worsening hepatic or renal function in decompensated cirrhosis

7. Drug Interactions

Sofosbuvir has a low potential for clinically significant drug-drug interactions due to its minimal metabolism via CYP450 enzymes. However, caution is warranted with:

• Drugs that alter renal excretion: Avoid concurrent use of nephrotoxic agents or those requiring renal adjustment.
• Ribavirin: Adds risk of hemolytic anemia; monitor CBC closely.
• Other DAAs: Potential additive hepatotoxicity (e.g., with glecaprevir/pibrentasvir).
• Warfarin: Monitor INR due to possible altered anticoagulation.

Major Interactions:

• Amiodarone, carbamazepine, phenytoin, rifampin, etc.: May reduce sofosbuvir levels or increase toxicity risk.
• P-gp inhibitors (e.g., verapamil): May increase sofosbuvir exposure.

Pharmacists should review all concomitant medications and adjust therapy as needed under physician supervision.

8. Special Populations

• Pregnancy: Limited data; use only if benefits outweigh risks.
• Lactation: Excreted in breast milk; avoid breastfeeding while on therapy.
• Elderly/Decompensated Cirrhosis: Use with caution, monitor for adverse effects and renal function.

9. Storage and Stability

• Store at 20–25°C (68–77°F), protected from moisture and light
• Do not freeze
• Shelf life: Typically 2–3 years from manufacture date

10. Monitoring and Safety

• Baseline and periodic assessment of liver function, renal function, and viral load
• Monitor for signs of hypersensitivity or hemolysis (especially with ribavirin)
• Watch for signs of worsening hepatic or renal function in patients with advanced disease

11. Summary for Clinical Practice

Sofosbuvir is a cornerstone of modern HCV therapy due to its efficacy, safety, and tolerability profile. Pharmacists play a vital role in:

• Ensuring correct dosing and regimen selection
• Monitoring for adverse effects and drug interactions
• Educating patients on adherence and potential risks

References:

• AASLD/IDSA HCV Guidance (2022)
• FDA Prescribing Information
• UpToDate: Hepatitis C treatment with direct-acting antivirals

In summary, sofosbuvir is a highly effective, well-tolerated DAA that has revolutionized HCV therapy. Pharmacists should be familiar with its pharmacology, interactions, and clinical use to optimize patient outcomes.